BRAF and melanoma: Longitudinal ctDNA assessment predicts progression-free survival and overall survival in stage IV melanoma patients treated with BRAF and MEK inhibitors or immunotherapy [13,14,15] and the melanoma-specific survival of patients with high-risk stage III resected melanoma [16].